ASH Annual Meeting 2022
ASH Annual Meeting 2022
Advertisement
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
Patients who recover from grade 3-4 acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell ...
Read More
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
Researchers, led by Mark A. Schroeder, MD, conducted a single-arm, open-label phase 1 trial to evaluate the safety of ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
Haploidentical blood and marrow transplantation (BMT) has significantly increased the number of eligible hematopoietic ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
At the 64th ASH Annual Meeting and Exposition, researchers presented early findings from the dose-finding portion of ...
Cailin ConnerASH Annual Meeting 2022 | May 2, 2023
Chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow that progresses over time, is one of the most ...
Cailin ConnerASH Annual Meeting 2022 | May 2, 2023
“Patients with chronic lymphocytic leukemia [CLL] have a higher risk of developing second primary malignancies ...
Cailin ConnerASH Annual Meeting 2022 | May 2, 2023
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that progresses over time. The number of ...
Cailin ConnerASH Annual Meeting 2022 | May 2, 2023
In patients with chronic lymphocytic leukemia (CLL), targeted therapies significantly improve clinical outcomes and ...
Cailin ConnerASH Annual Meeting 2022 | May 2, 2023
A research paper presented by Andrea Visentin, MD, PhD, of the University of Padova in Italy, and colleagues at the 64th ...
Patrick DalyASH Annual Meeting 2022 | September 26, 2023
According to Harinder Gill, MD, MBBS, FRCP, FRCPath, there is no optimal treatment strategy established for patients ...
Patrick DalyASH Annual Meeting 2022 | September 26, 2023
In the phase 2 MANIFEST trial, John Mascarenhas, MD, and colleagues evaluated pelabresib, an oral bromodomain and ...
Patrick DalyASH Annual Meeting 2022 | September 26, 2023
Studies have shown the JAK2 V617F somatic driver mutation is associated with disease progression in patients with ...
Patrick DalyASH Annual Meeting 2022 | September 26, 2023
Researchers from the Division of Hematology at Mayo Clinic, led by Naseema Gangat, MBBS, sought to identify predictors ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
In a presentation at the 64th ASH Annual Meeting and Exposition, Franco Locatelli, MD, presented the first evidence ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
Previously, Katiri Snyder and colleagues determined that the enzyme protein arginine methyltransferase 5 (PRMT5) was ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
In a presentation at the 64th ASH Annual Meeting and Exposition, researchers presented findings from a pilot study on ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
Studies suggest that between 35% and 60% of patients with acute graft-versus-host disease (aGVHD) become resistant to ...
Patrick DalyASH Annual Meeting 2022 | August 28, 2023
In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
In a phase 2 trial, presented at the 64th ASH Annual Meeting and Exposition, researchers compared itacitinib monotherapy ...
Advertisement
Advertisement
Advertisement
Latest News

March 28, 2024